DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Aarskog-Scott syndrome, X-linked — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAarskog-Scott syndrome, X-linked maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for aarskog-scott syndrome, x-linked is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
CD8 subunit alpha (CD8A) — CD8A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6-formyl-4-oxo-3,4-dihydropteridin-2-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7UMG · 2.4 Å · ligand N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide (30W). Experimental structure, not a prediction.
What the evidence adds up to
Aarskog-Scott syndrome is an X-linked developmental disorder with a relative prevalence of 1 in 25,000. Linkage studies from 1994, using DNA probes in two families, confirmed the gene localisation to the pericentromeric region of the X chromosome, with multipoint analysis indicating the most likely position on the proximal short arm. A 2012 report described a kindred of five affected males with a novel nonsense mutation of FGD1, who also presented with symmetric distal arthropathy and electromyographic signs of myopathy. A 2015 case report described a 10-year-old boy with the syndrome who was on growth hormone therapy and responding well, alongside a rehabilitation programme and genetic counselling for his family.
A 2016 review states that mutations of the FGD1 gene account for only 20% of the incidence of the disorder. Failure to identify pathogenic variants in patients referred for FGD1 screening suggests heterogeneity underlying the pathophysiology. The review notes that overlapping features with other developmental disorders increase diagnostic complexity, and that cytoskeletal signalling, specifically the role of FGD1 in activating CDC42, may be involved. It suggests that mutations in components of the EGFR1 signalling pathway, to which CDC42 belongs, may contribute to pathophysiology.
No drug treatment beyond growth hormone therapy in a single case is reported in these abstracts. No controlled trial of any drug for Aarskog-Scott syndrome is described. What is missing is any randomised trial of growth hormone or any other agent, any systematic attempt to stratify patients by FGD1 mutation status or by the presence of myopathy or arthropathy, and the funding to recruit the very small number of patients needed for such studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 1994 · 22 citations
Aarskog‐Scott syndrome: Confirmation of linkage to the pericentromeric region of the X chromosome
AbstractAarskog-Scott syndrome was tentatively mapped to Xq13 on the basis of an X:8 translocation by Bawle et al. [Am J Med Genet 17:595-602, 1984]. A review of the cytogenetics and the use of molecular markers in that family have resulted in revision of the breakpoints of the translocation to Xp 11.2 and 8q11.21 [Glover et al., Hum Mol Genet 2:1717-1718, 1993]. Two families, including one of the two initial families with Aarskog-Scott syndrome [Scott, BD:OAS VII (6): 240-246, 1971], have participated in our study to evaluate the localization of the gene for Aarskog-Scott syndrome to the pericentromeric region of the X chromosome. Using a series of DNA probes, we have been able to confirm linkage to the X chromosome, with multipoint analysis indicating the most likely localization of the gene to be on the proximal short arm.
Novel FGD1 mutation underlying Aarskog–Scott syndrome with myopathy and distal arthropathy
AbstractIn this report, we describe a kindred consisting of five affected males presenting with many of the well-recognized features of Aarskog-Scott syndrome. The diagnosis, which was confirmed by the identification of a novel nonsense mutation of FGD1, was associated with the presence of a symmetric distal arthropathy with electromyographic signs of myopathy. These features should be considered in the evaluation of future patients.
CHRISMED Journal of Health and Research · 2015 · 0 citations · open access
Aarskog–Scott syndrome: A perspective on growth and the influence of growth hormone therapy: Case-based review of literature
AbstractAarskog–Scott syndrome is an X-linked inherited disease characterized by short stature, facial abnormalities, skeletal, and genital anomalies. Although ophthalmic, dental, and cardiac defects are rarely seen. The present case report is of a 10-year-old boy with Aarskog syndrome who born with third degree of consanguineous marriage, delivered by caesarean section. The boy had triangular facies, maxillary hypoplasia, short neck, hypoplastic ear lobes, drooping shoulders, clinodactyly, single palmar crease, shawl scrotum. The patient was on growth hormone (GH) therapy and responding well. Along with GH therapy, the patient was on rehabilitation program and his family was undergoing genetic counseling.
Greater South Information System · 2016 · 0 citations · open access
Aarskog-Scott syndrome: phenotypic and genetic heterogeneity
AbstractAbstract Aarskog-Scott syndrome (AAS) is a rare developmental disorder which primarily affects males and has a relative prevalence of 1 in 25,000 in the general population. AAS patients usually present with developmental complications including short stature and facial, skeletal and urogenital anomalies. The spectrum of genotype-phenotype correlations in AAS is unclear and mutations of the FGD1 gene on the proximal short arm of chromosome X account for only 20% of the incidence of the disorder. Failure to identify pathogenic variants in patients referred for FGD1 screening suggests heterogeneity underlying pathophysiology of the condition. Furthermore, overlapping features of AAS with several other developmental disorders increase the complexity of diagnosis. Cytoskeletal signaling may be involved in the pathophysiology of AAS. The FGD1 protein family has a role in activation of CDC42 (Cell Division Control protein 42 homolog) which has a core function in remodeling of extracellular matrix and the transcriptional activation of many modulators of development. Therefore, mutations in components in the EGFR1 (Epidermal Growth Factor Receptor 1) signaling pathway, to which CDC42 belongs, may contribute to pathophysiology. Parallel sequencing strategies (so-called next generation sequencing or high throughput sequencing) enables simultaneous production of millions of sequencing reads that enormously facilitate cost-effective identification of cryptic mutations in heterogeneous monogenic disorders. Here we review the source of phenotypic and genetic heterogeneity in the context of AAS and discuss the applicability of next generation sequencing for identification of novel mutations underlying AAS.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
